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Ideal vaccines against inﬂuenza viruses should elicit not only a humoral response, but also a cellular
response.Mycobacterium tuberculosis HSP70 (mHSP70) have been found to promote immunogenic APCs
function, elicit a strong cytotoxic T lymphocyte (CTL) response, and prevent the induction of tolerance.
Moreover, it showed linkage of antigens to the C-terminus of mHSP70 (mHSP70c) can represent them
as vaccines resulted in more potent, protective antigen speciﬁc responses in the absence of adjuvants or
complex formulations. Hence, recombinant fusion protein comprising C-terminus of mHSP70 geneti-
cally fused to four tandem repeats of the ectodomain of the conserved inﬂuenza matrix protein
M2 (M2e) was expressed in Escherichia coli, puriﬁed under denaturing condition, refolding, and then
conﬁrmed by SDS–PAGE, respectively. The recombinant fusion protein, 4xM2e.HSP70c, retained its
immunogenicity and displayed the protective epitope of M2e by ELISA and FITC assays. A prime-boost
administration of 4xM2e.HSP70c formulated in F105 buffer by intramuscular route in mice (Balb/C)
provided full protection against lethal dose of mouse-adapted H1N1, H3N2, or H9N2 inﬂuenza A
isolates from Iran compared to 0–33.34% survival rate of challenged unimmunized and immunized
mice with the currently in use conventional vaccines designated as control groups. However, protection
induced by immunization with 4xM2e.HSP70c failed to prevent weight loss in challenged mice; they
experienced signiﬁcantly lower weight loss, clinical symptoms and higher lung viral clearance in
comparison with protective effects of conventional inﬂuenza vaccines in challenged mice. These data
demonstrate that C-terminal domain of mHSP70 can be a superior candidate to deliver the adjuvant
function in M2e-based inﬂuenza A vaccine in order to provide signiﬁcant protection against multiple
inﬂuenza A virus strains.
& 2012 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza A viruses are globally important respiratory patho-
gen which cause a high degree of morbidity and mortality during
annual epidemics (Cox et al., 2004).
The recent emergence of highly virulent avian inﬂuenza,
H5N1, and swine-origin H1N1 showed a threat not only to the
poultry industry, but also to wild birds, several species of
mammalians, and humans in contact with such species (Garten
et al., 2009; Malik Peiris et al., 2007).ll rights reserved.Because of growing evidence for increased incidence of differ-
ent subtypes of inﬂuenza A virus in both animal and human
population worldwide and failure of vaccination with conven-
tional vaccines due to frequent antigenicity changes resulting
from antigen drift and antigen shift, bring out an urgent need to
develop a universal inﬂuenza vaccine, which could provide cross-
protection against different inﬂuenza virus strains (Brett et al.,
2005; Ebrahimi et al., 2011a, b; Fan et al., 2007; Johansson et al.,
1989). The development of a truly universal vaccine would
present the potential opportunity for both reducing the threat
of a pandemic and the impact of seasonal inﬂuenza.
One candidate protein for such a vaccine is matrix protein 2
(M2), a 97 amino acid (aa) transmembrane and nonglycosylated
protein of inﬂuenza A virus, whose extracellular domain with
24 aa residues (23 aa after posttranslational removal of the
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mature M2 protein forms homotetramers and functions as a
proton-selective channel and is important for uncoating of viral
particles in endosomes for viral entry, in which the virion releases
the vRNP from M1 such that vRNP is free to enter the host cell’s
cytoplasm (Ciampor et al., 1992; Lamb et al., 1985).
M2e, which consists of N-terminal 24 residues, is remarkably
conserved, and the ﬁrst 9 amino acid residues are almost
conserved among all subtypes of inﬂuenza A viruses (Fiers et al.,
2004; Liu et al., 2005).
One of the concerns about inﬂuenza A vaccines based on M2e
protein is their limited potency; hence, it seems the immunogenicity
of the M2e can be increased by delivery in multimeric form or in
combination with complex adjuvants or delivery systems.
Thus, numerous small-scale experimental studies using var-
ious M2e-based vaccines, mostly M2e fusion constructs, have
reported the value of vaccination in protecting mouse models and
occasionally ferret against inﬂuenza A virus challenges.
So far, various approaches for increasing the potency of M2e as
vaccine candidate were done including M2e peptide has been
chemically conjugated to protein carriers such as keyhole limpet
hemocyanin (KLH), BSA, or Neisseria meningitidis outer membrane
protein complex (OMPC), to provide T helper cell epitopes (Fan
et al., 2004; Liu et al., 2003).
The other strategies are genetic insertion of M2e into the HBVc
open reading frame as M2e-HBc and toll-like receptor 5 (TLR5)
ligand salmonella typhimurium ﬂagellin type 2 as M2e-ﬂagellin
(Huleatt et al., 2008; Jegerlehner et al., 2002; Neirynck et al., 1999).
Consequently, these studies have shown that immunization of
mice with above mentioned M2e-based vaccine can protect them
against lethal dose of homosubtypic and heterosubtypic inﬂuenza
A infection. Protection was measured by reduced host morbidity,
host mortality and virus shedding following challenge with
human or avian inﬂuenza A viruses. M2e-HBc and M2e-ﬂagellin
have recently been evaluated for their safety and immunogenicity
in human phase I and I/II clinical trials with promising results,
respectively (De Filette et al., 2008; Turley et al., 2011).
In this study for the ﬁrst time, we have produced an E. coli-
expressed fusion protein, 4xM2e.HSP70c, comprising of four
tandem repeats of a consensus M2e sequence genetically fused
to the N-terminus of adjuvant fragment of Mycobacterial HSP70
(mHSP70359–610aa or mHSP70c). We then evaluated the potency
and protectivity of this construction in mouse model against
lethal dose of mouse-adapted H1N1, H3N2, or H9N2 inﬂuenza A
isolates from Iran in comparison with protective effects of con-
ventional inﬂuenza vaccines.
Mycobacterial HSP70 was proved to act as adjuvants and
augment the immunogenicity of weak antigens. Moreover, pro-
teins or peptides fused with HSP70 when used for immunizations
in mice have shown to yield desirable humoral and cellular
immune responses (Suzue and Young, 1996; Suzue et al., 1997;
Udono et al., 2001).
Suzue and Young (1996) showed that antigen linked cova-
lently with mHSP70 as fusion proteins induce better humoral and
cellular responses than the antigen alone.Fig. 1. Schematic representation of a construct encoding four copies of M2e fused to
HSP70c genes, ampliﬁed separately by speciﬁc primers containing determined restrictio
by Roche Co., according to manufacturer’s protocol. The products were then single dige
gel-puriﬁed and ligated by T4 DNA ligase produced by Roche Co., to form 4xM2e.HSP7
between adjacent proteins, each protein was separated from its neighboring one by aCho et al. (2000) showed that HSP70-antigen fusion proteins
are capable of inducing speciﬁc CD8þCTL response to peptides in
the absence of other adjuvants and even without requiring any
activation of CD4þT-cells. It was also reported that vaccines
containing E7-HSP70 fusion genes, in which E7 was derived from
human papillomavirus type 16 E7 and HSP70 from mycobacter-
ium tuberculosis, could increase the frequency of E7-speciﬁc
CD8þ T cells in mice by at least 30-fold relative to vaccine
containing the wild- type E7 gene (Chen et al., 2000). In other
studies, the effects of HSP70359–610 on foot and mouth virus
(FMDV) and Japanese encephalitis virus (JEV) in mice were
evaluated separately and the HSP70 markedly enhanced both
the humoral and cell-mediated immune responses (Chunxia et al.,
2006; Fei-fei et al., 2006).
It was also shown that the C-terminal fragment of HSP70 fused
to the malarial antigen EB200 (HSP70-EB200) induced MHC
responses considerably (Qazi et al., 2005).
Here, we also showed that a prime-boost administration of
4xM2e.HSP70c formulated in F105 buffer by intramuscular route
in mice (Balb/C) provided full protection against lethal dose of
mouse-adapted H1N1, H3N2, or H9N2 inﬂuenza A isolates from
Iran compared to 0–33.34% survival rate of challenged unimmu-
nized and immunized mice with the currently in use conventional
vaccines designated as control groups. However, protection
induced by immunization with 4xM2e.HSP70c failed to prevent
weight loss in challenged mice, but they experienced signiﬁcantly
lower weight loss, clinical symptoms and higher lung viral
clearance in comparison with protective effects of conventional
inﬂuenza vaccines in challenged mice.Results
Production of the recombinant fusion proteins
Previously we have demonstrated that genetically fusing single
copy of M2e derived from the avian inﬂuenza A H9N2 virus to the
mHSP70c markedly enhances the immunogenicity of the E.coli-
expressed fusion protein in rabbits (Ebrahimi and Tebianian, 2010).
Consequently, a recombinant fusion protein comprising C-termi-
nus of mHSP70 (mHSP70c), which can interact with CD91, TLR4,
TLR2, and CD40 receptors on antigen-presenting cells (APCs),
genetically fused to four tandem repeats of the ectodomain of the
conserved inﬂuenza matrix protein M2 (M2e) was cloned into
pQE-60 vector and then expressed in Escherichia coli strain M15.
The recombinant fusion protein, 4xM2e.HSP70c, with a
C-terminal histidine (His)-tagged was puriﬁed under denaturing
condition, refolding, and then analyzed in SDS–PAGE. An approxi-
mately 40 kDa band corresponding to 4xM2e.HSP70c fusion
protein was readily visible by Coomassie Blue and by immunoblot
using either of commercial penta-His HRP conjugated antibody
(Sigma-Aldrich, USA), anti-HSP70 (Abcam, UK) or anti-M2
(Abcam, UK) antibodies (data not shown).
The recombinant fusion protein 4xM2e.HSP70c (carrying four
copies of M2e) retained its immunogenicity and displayed theHSP70c gene as a one open reading frame (1100 bp). The fragments, M2e and
n enzymes were gel-puriﬁed using high pure PCR product puriﬁcation kit produced
sted with BamHI restriction enzyme separately. The digested products were again
0c gene as a single ORF in a pQE-60 ecpression vector. To minimize interference
glycine and a serine codon.
Fig. 2. M2e speciﬁc antibodies (1:400 diluted in PBS) were determined by ELISA.
96-well plates were coated with peptide M2e. Anti-sera were collected 13 days
after the ﬁrst immunization (1st immun) and the second immunization (boost 1),
respectively, from mice immunized with 4xM2e.HSP70c administrated in F105
buffer. The bound antibodies were detected by horseradish peroxidase-linked
rabbit-anti-mouse antibodies and TMB solution. Mean value7S.E.M of A450 in
each group were presented. The titers of antibodies were expressed as the highest
dilution of a serum which has twice average value of A450 in control group. Bars
show mean value7standard error of the mean (S.E.M) of ﬁve mice/group per time
point. The dashed line shows the limit of detection. Mean with different letters
between bars are statistically different at the same time point (po0.05).
Fig. 3. Mean hemagglutinin-inhibition (HI) antibody titers from mice immunized
with split- or subunit- conventional vaccines and 4xM2e.HSP70c recombinant
fusion protein 13 days after the ﬁrst immunization (1st immun) and the second
immunization (boost 1), respectively. b-propiolactone (BPL)-treated Iran/H1N1
antigen was used in HI assay for analysis of anti HA-antibody responses induced
by conventional vaccines. The mean titers of antibodies enhancement with HA
glycoprotein were detected in mice vaccinated with 4xM2e.HSP70c fusion protein
on 7 and 14 day post infections (7DPI and 14DPI) by using homologous
BPL-treated Iran/H3N2, Iran/H1N1, or Iran/H9N2 antigens. Bars show log 2
geometric mean7standard error of the mean (S.E.M) of ﬁve mice/group per time
point. The dashed line shows the limit of detection. Mean with different letters
between bars are statistically different at the same time point (po0.05).
n (7 Infection) indicates as before () or after (þ) infection.
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peptide, sera from immunized and unimmunized mice, and
commercial anti-mouse HRP conjugated antibody (Fig. 2), accord-
ing to the methods described by our previous studies (Ebrahimi
and Tebianian, 2010). In addition, the results of FITC assay also
conﬁrmed the correct exposure of protective epitope of M2e in
which only anti-M2e protein IgG Abs taken from immunized mice
could bind M2 on cells infected with H1N1, H3N2, or H9N2
inﬂuenza A isolates; however, the absence of ﬂuorescence emis-
sion in uninfected cells showed the speciﬁcity of the experiment
(data not shown). This allows two conclusions. First, Abs induced
against M2e-based vaccine, 4xM2e.HSP70c, are cross-reactive
with a protein expressed on either of virus-infected cells, appar-
ently native M2 protein. Second, Abs can act as an effective role in
clearance of infected cells in hosts by binding to the surface of
infected cells (Jegerlehner et al., 2004). Thus, these data suggest
that the antibody induced against 4xM2e.HSP70c could protect
the host against virus challenge through antibody dependent cell-
mediated cytotoxicity (ADCC) and Ab-dependent cell-mediated
phagoctosis as recently reported by Bakkouri et al. (2011).
Serologic response to immunization
Polyclonal serum from mice immunized with M2e-based
vaccines or commercial vaccines were analyzed by ELISA and HI
assays to identify IgG antibodies directed against M2e peptide or
HA glycoprotein of inﬂuenza A isolates, respectively.
No anti-M2e or anti-HA antibody was detected in mice of
different groups prior to vaccination. All mice initially immunized
and subsequently boosted with M2e-based vaccine or commercial
vaccines containing HA had an anti-M2e (Fig. 2) and anti-HA
(Fig. 3) antibody responses as measured by ELISA and HI assays,
respectively.
All mice initially immunized and subsequently boosted with
commercial vaccines containing HA had an anti-HA antibody
response as measured by HI assay (Fig. 3). No anti-M2e antibody
was detected in mice immunized with commercial vaccines.
There was no statistically signiﬁcant differences between groups
of mice immunized with split or subunit commercial vaccine(Fig. 3; P40.05). However, mice immunized with split vaccine
showed relatively higher titer of anti-HA antibody than observed
with subunit vaccine.
No anti-HA antibody was produced in mice immunized with
4xM2e.HSP70c as measured by HI assay, prior to viral challenge.
However, the mean titers of antibodies enhancement with HA
glycoprotein were detected in mice vaccinated with 4xM2e.HSP70c
fusion protein on days 7 and 14 after challenges by using homo-
logous BPL-treated viruses antigen (Fig. 3). A lower mean titer of
anti-HA antibody was induced by virus infections in the mice
immunized with 4xM2e.HSP70c than observed with conventional
vaccines containing HA (Fig. 3; Po0.05), indicating that the chal-
lenge viruses in the 4xM2e.HSP70c immunized groups of mice were
not sufﬁcient to induce an antibody boost.
Moreover, there was no signiﬁcant difference in induced anti-
HA antibodies among 4xM2e.HSP70c immunized groups of mice
on day 14 after challenge with either of mentioned viral isolates
(data not shown; P40.05).
The signiﬁcant increase on anti-HA antibody titers on day 14
after viral challenges in both conventional and M2e-based vacci-
nated mice further indicated a replicative infection of the chal-
lenge viruses in these mice (Fig. 3). These data conﬁrm that
inactivated conventional vaccines could not protect against clin-
ical signs and mortality in mice. In contrast, 4xM2e.HSP70c fusion
protein as a vaccine candidate signiﬁcantly decreased clinical
signs, lungs viral load, and fully protected mice against hetero-or
homosubtypic virus challenges, but this did not fully prevent
infection.
Vaccination with M2e-based vaccines protected mice against
inﬂuenza virus challenge
To evaluate the potency of the 4xM2e.HSP70c fusion protein
against lethal inﬂuenza virus challenges, Balb/C mice were
immunized twice as described above and challenged intranasally
with a 90% lethal dose (LD90) of mouse adapted H3N2, H1N1, or
H9N2 inﬂuenza A isolates on day 14 after the last immunization.
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clinical signs and percent survival.
The mice were monitored for adverse reactions to the vaccina-
tion procedure including redness, swelling, and the formation of
granulomas at the site of injection. No macroscopic signs of
adverse reactions to the 4xM2e.HSP70c fusion protein were
observed.
Following the challenge, animals were monitored for weight
change (as a measure of illness) and mortality. As expected, the
LD90 challenge of mouse-adapted H1N1, H3N2, or H9N2 inﬂuenza
virus isolates resulted in 100% mortality in the non-vaccinated
groups (Fig. 4A–C, Tables 2–4). In contrast, 100% of mice immunized
with 4xM2e.HSP70c survived against H3N2, H1N1, or H9N2 viral
challenges, respectively (Fig. 4A–C, Tables 2–4), and began to
recover on day 8 post-challenge. Of mice vaccinated with egg-
derived subunit vaccine 33.34% (7 of 21 mice), 14.29% (3 of 21 mice),
and 23.81% (5 of 21 mice) survived challenge with H3N2, H1N1, or
H9N2, respectively (Fig. 4A–C, Tables 2–4), and began to recover on
day 9–10 post-challenge. Of mice vaccinated with egg-derived split
vaccine 28.58% (6 of 21 mice), 19.05% (4 of 21 mice) and 28.58%
(6 of 21 mice) survived challenge with H3N2, H1N1, or H9N2
inﬂuenza isolates, respectively (Fig. 4A–C, Tables 2–4), and began to
recover on day 9–10 post-challenge. Thus, in contrast to commercial
vaccines (split or subunit), M2e-based vaccines protected against
challenge viruses in which M2e sequences were similar to or
divergent from those of the vaccine. In general, the differences in
survival of 4xM2e.HSP70c immunized groups of mice following
challenges with compared to other groups of infected mice were
highly signiﬁcant (Fig. 4A–C, Tables 2–4; Po0.05).
Immunized mice with M2e-based vaccines showed signiﬁcant
weight loss following the viral challenges; however, this was less
severe than that observed for the challenged non-vaccinated mice
and mice vaccinated by split or subunit commercial vaccines. TheFig. 4. Results of prime-boost immunization with 4xM2e.HSP70c recombinant fusion p
vaccines in mice (21 mice/group) and challenges with lethal dose (MLD90) of mouse-ada
were challenges as negative controls. Survival rate (A–C; panels are based on viral cha
(D–F; panels are based on viral challenge isolate with standard error bars) were monito
difference between 4xM2e.HSP70c immunized mice with other groups (Po0.05).differences in body weight loss of 4xM2e.HSP70c immunized
groups of mice following viral challenges with compared to other
groups of challenged mice were also highly signiﬁcant (Fig. 4D–F;
Po0.05).
In all experiments, morbidity following challenges was mon-
itored by measuring body weight and observation of clinical
symptoms. There was usually a weight loss after challenges, even
in the fully protected groups (Fig. 4D–F). It seems that the
incomplete prevention of morbidity may be explained by the
severity of the viral challenge. A highly lethal dose for challenge
ensures that all, or nearly all, control mice will die as a conse-
quence, and unambiguously conﬁrms the protective efﬁcacy of
the vaccine. These results suggest that this strategy for develop-
ment of M2e-based vaccine could induce fully protection against
homo -and heterosubtypic inﬂuenza A viral challenges in mice.
Clinical signs, histopathologic examination and lung viral load
Following the inoculation of mice against a lethal dose of
H3N2, H1N1, or H9N2 inﬂuenza virus isolates; the vaccinated
mice were further evaluated in terms of cross-protective ability
by daily observation of the clinical symptoms, viral shedding rate
and then histopathological examination following removal of
lung tissues compared to the unchallenged control group of mice.
Unchallenged mice in the negative control group (Table 1;
group 1) remained negative for virus shedding and clinical sings
throughout the study period (data not shown).
From day 3 after viral challenges, the challenged and non-
vaccinated mice developed obvious clinical signs including:
rufﬂed fur, hunched posture, rapid breathing, inactivity and
paralysis of posterior limb. These clinical signs were delayed for
2–3 days in the mice vaccinated with the 4xM2e.HSP70c fusion
protein, in which they exhibited mild clinical signs for 3–4 daysrotein administrated in F105 buffer and conventional egg-derived subunit-or split
pted H1N1, H3N2, or H9N2 inﬂuenza A isolates. Mice immunized with F105 buffer
llenge isolate) were monitored on a daily basis and percent of initial body weight
red at two-day intervals for 2 weeks after viral challenges. n Indicates statistically
Table 1
Experimental design vaccination status, Inﬂuenza virus infection status and
number of mice per group.
Groups Vaccination Challenge virus Total number
of mice
1 F105 buffer No 30
2 4xM2e.HSP70c H1N1 30
3 Subunit vaccine H1N1 30
4 Split vaccine H1N1 30
5 F105 buffer H1N1 30
6 4xM2e.HSP70c H3N2 30
7 Subunit vaccine H3N2 30
8 Split vaccine H3N2 30
9 F105 buffer H3N2 30
10 4xM2e.HSP70c H9N2 30
11 Subunit vaccine H9N2 30
12 Split vaccine H9N2 30
13 F105 buffer H9N2 30
Table 2
Pulmonary viral replication of either immunized or unimmunized mice following
challenges with mouse adapted (m.a.) H1N1 isolate of inﬂuenza virus circulating
in Iran on 3, 6, and 9 days post infection (dpi). Numbers show log 10 geometric
mean TCID50/ml7standard error of the mean (S.E.M) of three mice/group per
time point. Mean with different letters within columns (same dpi) are statistically
different (po0.05).
Mean viral titers (log10 TCID50/ml)7S.E.M
Groups 3 dpi 6 dpi 9 dpi Mortality (no.of
dead/no. of challenged)
4xM2e.HSP70c 3.070.18a 2.170.22a o0.9B 0/21a
Subunit vaccine 5.970.44b 4.570.25b r1.8 18/21b
Split vaccine 6.170.33b 4.970.50b r1.9 17/21b
F105 buffer 7.970.55c 6.870.49c r2.7 21/21c
BMean viral titers (log10 TCID50/ml)7S.E.M on 9 dpi was determined below the
level of detection (o0.9).
Table 3
Pulmonary viral replication of either immunized or unimmunized mice following
challenges with mouse adapted (m.a.) H3N2 isolate of inﬂuenza virus circulating
in Iran on 3, 6, and 9 day post infection (dpi). Numbers show log10 geometric
mean TCID50/ml7standard error of the mean (S.E.M) of three mice/group per
time point. Mean with different letters within columns (same dpi) are statistically
different (po0.05).
Mean viral titers (log10 TCID50/ml)7S.E.M
Groups 3 dpi 6 dpi 9 dpi Mortality (no. of
dead/no. of challenged)
4xM2e.HSP70c 3.270.12a 2.370.14a o0.9B 0/21a
Subunit vaccine 4.870.15b 3.970.22b r1.2 14/21b
Split vaccine 5.570.24b 4.170.12b r1.6 15/21b
F105 buffer 7.370.31c 6.170.22c r2.5 21/21c
BMean viral titers (log10 TCID50/ml)7S.E.M on 9 dpi was determined below the
level of detection (o0.9).
Table 4
Pulmonary viral replication of either immunized or unimmunized mice following
challenges with mouse adapted (m.a.) H9N2 isolate of avian inﬂuenza circulating
in Iran on 3, 6, and 9 days post infection (dpi). Numbers show log 10 geometric
mean TCID50/ml7standard error of the mean (S.E.M) of three mice/group per
time point. Mean with different letters within columns (same dpi) are statistically
different (po0.05).
Mean viral titers (log10 TCID50/ml)7S.E.M
Groups 3 dpi 6 dpi 9 dpi Mortality (no. of
dead/no. of challenged)
4xM2e.HSP70c 3.570.18a 2.670.15a o0.9b 0/21a
Subunit vaccine 5.670.34B 4.970.25b r2.1 16/21b
Split vaccine 5.370.30b 4.570.17b r1.9 15/21
F105 buffer 6.870.39c 5.570.18c r2.3 21/21c
BMean viral titers (log10 TCID50/ml)7S.E.M on 9 dpi was determined below the
level of detection (o0.9).
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challenge with the heterosubtypic inﬂuenza virus, H9N2, demon-
strated mildly increased clinical signs compared to those chal-
lenged with the homosubtypic viruses, H1N1 or H3N2, but the
difference in the mortality rate between them was not signiﬁcant.
Moreover, compared to the challenged and non-vaccinated
groups of mice (Table 1; groups 5, 9 and 13), the subunit- or split-
vaccinated mice that did not survive the challenges were observed
to have delayed the onset of illness and longer survival days.
Grass pathology of lungs in all challenged control mice and
subunit- or split-vaccinated mice on day 6 after infection showed
multiple foci of hemorrhage visible on the surface. Lungs of mice
vaccinated with 4xM2e.HSP70c fusion protein showed a few focal
areas of hemorrhage on the surface on day 6 after infection (data
not shown).
Light microscopy observations, including damage of bronchial
epithelium with necrosis, congestion, lymphocytic inﬁltration,
and edema were consistent with the gross examinations among
challenged groups (data not shown).
To further determine the effect of 4xM2e.HSP70c fusion
protein as a universal vaccine candidate on viral replication in
the respiratory system of mice, we evaluated the lung viral load
from all challenged mice on days 3, 6, and 9 after viral challenges
(Tables 2–4).
No virus was isolated from the lungs of the unchallenged control
mice (Table 1; group 1). All challenged mice showed pulmonary viral
replication at days 3 and 6 after challenges with H3N2, H1N1, or
H9N2 inﬂuenza virus isolates. Mice immunized with 4xM2e.HSP70cfusion protein had overall signiﬁcantly lower lung viral load than did
the challenged control groups or challenged subunit-or split-vacci-
nated mice (Tables 2–4; po0.05).
At day 9 after challenge, no viruses were detected in the mice
immunized with 4xM2e.HSP70c fusion protein; whereas, viruses
were detected in the challenged control mice and subunit-or
split-vaccinated mice (Tables 2–4). With regard to periods of viral
shedding, the mice that received 4xM2e.HSP70c fusion protein
had lower periods of virus replication and this suggest this
recombinant fusion protein as a universal vaccine candidate can
induce protective immunity against heterosubtypic virus, H9N2,
and homosubtypic viruses, H1N1 or H3N2, in vaccinated mice.Discussion
There is a continuing need for improved inﬂuenza A vaccines
to provide a broader and longer lasting immunity. The develop-
ment of a truly universal vaccine would present the potential
opportunity for both reducing the threat of a pandemic and
the impact of seasonal inﬂuenza. M2e protein-based vaccine
approaches represent one such vaccine as its N-terminal epitope
SLLTEVET (residues 2–9) found to be conserved at a rate of over
99.3% among all subtypes of inﬂuenza A viruses and 100% among
isolates from human (Fiers et al., 2004; Liu et al., 2005).
Previous studies have shown that vaccine-induced antibody
responses against M2e protein could protect animal models
(mostly mice) against lethal challenge of inﬂuenza A viruses.
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difference of carrier proteins, adjuvant, dose of viral challenge, or
route of vaccine administration (Fan et al., 2004; Fan et al., 2007;
Frace et al., 1999; Liu and Chen, 2005; Mozdzanowska et al.,
2003; Neirynck et al., 1999; Okuda et al., 2001; Slepushkin et al.,
1995).
Laboratory mouse has proven a useful tool for the study of
inﬂuenza viruses due to its utility in measuring infectivity,
pathogenesis, and subsequent application for the evaluation
of vaccine and antiviral candidates (Haga and Horimoto, 2010;
Lu et al., 1999).
Hence, in the present study for the ﬁrst time we used the
C-terminal fragment of mycobacterial HSP70 as a potent carrier to
develop an effective M2e-based recombinant vaccine in order
to stimulate CD8þ T cell responses that are crucial to immune
responses against viruses.
Considering the successful results reported from preclinical
study with 4xM2e.Flagellin fusion protein vaccine candidate in
mice by Huleatt et al. (2008) and the recently published report of
relevant phase I/II clinical trials in human with promising results
include its good safety and potency (Turley et al., 2011). We
implemented a similar approach of M2e-based vaccine develop-
ment, but the adjuvant fragment of Mycobacterial HSP70
(mHSP70) as a potential approach to increase the potency of
M2e was used instead of ﬂagellin. The reason of linking M2e to
adjuvant portion of mHSP70 is that the targeting of antigen
to APCs through HSP70 receptors such as CD91 is a useful strategy
to induce CD8þ T cell and antibody responses by alternate MHC-I
Ag processing (cross-processing) mechanisms, resulting in cross-
presentation of the exogenous antigens to CD8þT cells that are
crucial to immune responses against viruses (Arnold et al., 1995;
Blachere et al., 1997; Castellino, 2000a, b; Tobian, 2004). More-
over, Hsp70 can also activate the innate immunity through CD40
and Toll-like receptor-2 (TLR-2) and TLR-4 to induce cytokine
secretion (Takakura et al., 2007; Takemoto et al., 2005).
Hence, based on our previous studies (Ebrahimi and Tebianian,
2010), we sought to construct a fusion plasmid harboring four
tandems repeats of the extracellular domain of the inﬂuenza A
M2 protein (M2e), which was fused to the N-terminus of
the truncated HSP70 (HSP70359–610) molecule. This chimeric
sequence was heterologously expressed in E.coli (M15 strain),
puriﬁed and further analyzed as a 4xM2e.HSP70c recombinant
fusion protein. The puriﬁed protein was formulated in F105 buffer
and then tested for its ability to stimulate immune responses and
level of its protectivity against viral challenges in comparison
with conventional inﬂuenza vaccines in mice.
The puriﬁed protein formulated in F105 buffer (in the absence
of other adjuvants) was able to induce strong and effective M2e-
speciﬁc immune responses in Balb/C mice and completely
retained its structural conformation so that the induced antibo-
dies against this recombinant protein was able to recognize and
bind to the native M2 antigen on the surface of infected cells by
either of H3N2, H1N1 or H9N2 inﬂuenza isolates.
We have also shown that genetically fusing an M2e to
adjuvant fragment of mHSP70 signiﬁcantly increased the immu-
nogenicity with the retained native epitopes in the absence of
other adjuvants is in consistent with previous studies in which
the adjuvancity role of the mHSP70c were reported (Cho et al.,
2000; Li et al., 2006; Suzue and Young, 1996).
To determine the optimal dosing schedule and route of
administration, mice were vaccinated with different doses of
4xM2e.HSP70c formulated in F105 buffer and then challenged with
inﬂuenza virus (PR8/H1N1) and monitored for survival. The results
from these studies established that a 9 mg dose of this fusion protein
by intramuscular route of injection was sufﬁcient to stimulate
immune responses and provide protection against viral challenge.This dose level and route of injection is comparable to that observed
for conventional haemagglutinin (H) vaccines preparation.
In contrast to the egg-derived split or subunit vaccines, which
is currently in use to provide immune protection against inﬂu-
enza viruses in Iran, immune response stimulated by the
4xM2e.HSP70c fusion protein fully protected the mice against
lethal dose of mouse-adapted H3N2, H1N1, or H9N2 isolates
circulating in Iran. The pronounced level of protection generated
by the 4xM2e.HSP70c fusion protein is probably related to the
interaction of the mHSP70c, which can activate the innate and
adaptive immunity through its speciﬁc receptors and the multiple
presentation of the M2e antigen.
From this data, several important observations can be made.
First, the four tandem repeats of inﬂuenza M2e antigen linked
genetically with mHSP70c as fusion protein induced the immune
responses to this antigen well. Second, in contrast to conventional
vaccines, the 4xM2e.HSP70c fusion protein as a vaccine candidate
provided a full level of protection against hetro-or homosubtypice
of inﬂuenza A virus challenges. Since the M2e sequences chosen
in this construct are homologous to most of the H1N1 and H3N2
strains infecting humans circulating in Iran.
Third, Vaccine to M2e is predicted to limit the severity of
inﬂuenza A disease by its inhibitory role on the uncoating of viral
particles in endosomes and preventing viral replication; conse-
quently, delaying the onset of morbidity in mice for 2–3 days
rather than other control groups can allow the host immune
response to develop adaptive immunity to the dominant neutra-
lizing inﬂuenza antigen, HA. Therefore, humeral immune
responses against HA provoked by infection could help to reduce
the lung viral replication and restricted histopathological damage
in lung tissues. Histopathologic analysis of lungs from such
infected mice immunized with 4xM2e.HSP70c fusion protein
revealed markedly reduced tissue injury, mononuclear cell accu-
mulation, hemorrhage, and pulmonary edema.
This explanation can be considered by the results of the
present study in which we detected inﬂuenza virus-induced
antibody by day 7 after challenge (Fig. 3) and previous studies
in which the early inﬂuenza virus-induced antibodies detected
systemically in the serum by day 5 to 6 after challenge; in other
words, 2–3 days after symptom onset (Fabrice et al., 2008; Lincoln
et al., 2010; Sealy et al., 2003), could have a signiﬁcant impact in
controlling viral replication, and thus contributes to a less severe
disease outcome (Baumgarth et al., 1994; Doherty et al., 1997).
In contrast, mice immunized with split or subunit conven-
tional vaccines did not result to decreased level of lung viral load,
morbidity, mortality, and histopathological damage in lung tis-
sues against lethal dose of viral challenges compared to mice
immunized with 4xM2e.HSP70c vaccine candidate. Whereas,
both of conventional vaccines induced high level of HA-antibody
in mice, but these derived antibodies could not reduce the level
and duration of viral replication in mice. This failure effects of
conventional vaccines in mice against H1N1 and H3N2 isolates
circulating in Iran can be expected and occur frequently as a
result of frequent point mutation (antigenic drift) of haemagglu-
tinin (HA) (Seo et al., 2002). This vaccine failure for H9N2 avian
inﬂuenza was also expected because of HA-mismatched among
those heterosubtypic strains. In addition, it seems the extreme
pathogenicity of the mentioned isolates of mouse adapted viruses
are directly linked to the high viral replication rate and the
consequent production of peak steady state viral titers in the
lungs within 48 h after infection so that the immune responses
could not restrict viral replication.
In the present study, we focused more on potential protectiv-
ity of the 4xM2e.HSP70c fusion protein as a universal inﬂuenza A
vaccine candidate in comparison with conventional vaccines
which have been using in Iran for more than one decade. This
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data, but assessment of antibody isotype and cytokine responses
have been completed and will be reported in detail in future.
The successful use of the adjuvant fragment of mycobacterial
HSP70, as an adjuvant for this vaccine candidate, is an innovative
approach to inducing immune response and protecting mice
against lethal challenge of inﬂuenza infections in the absence of
exogenous adjuvant. The use of mHSP70c as carriers seems to be
safe for the development of vaccine strategies, since most humans
have been in contact with mHSPs through BCG which is currently
used as a vaccine against tuberculosis, and a large number of
people are sensitized to mycobacteria or other parasites through
natural contacts.
Conclusion
Based on evidence to our ﬁnding, M2e fusion to HSP70 is
intrinsically very immunogenic and being able to protect mice
against lethal challenge of homo-or heterosubtypic inﬂuenza A
isolates, and 4xM2e.HSP70c recombinant fusion protein as a
universal inﬂuenza A vaccine candidate can be easily produced
in efﬁcient prokaryotic-expression systems that require minimal
containment. For these reasons, they are promising candidates for
further clinical evaluation to study its immunogenicity and safety
in people. Now, the results of preclinical studies on the recombi-
nant 4xM2e.HSP70c fusion protein have convinced the Iranian
health ofﬁcials to prepare conditions for beginning of Phase I
clinical trial as soon as possible, in which the safety and
immunogenicity of this recombinant fusion protein as a universal
inﬂuenza A vaccine will be tested.Materials and methods
Expression of recombinant 4xM2e.HSP70c fusion proteins
According to the study by Huleatt et al. (2008), a construct
encoding a single copy of M2e derived from the consensus
sequence of the human inﬂuenza A virus (H1N1, H2N1, H3N2;
amino acid sequence: SLLTEVETPIRNEWGCRCNDSSD) was chemi-
cally synthesized in pGH cloning vector, designated as pGHM2e
(Generay Biotech Co., Shanghai, China). In this synthetic gene the
two cysteine residues at sites 17 and 19 of M2e were modiﬁed to
serine (SLLTEVETPIRNEWGSRSNDSSD; the modiﬁed amino acids
are determined by bold and underlined letters), to prevent
disulﬁde bond formation that would be incompatible with Eschri-
chia coli expression since these cysteines could result in formation
of intramolecular disulﬁde bonds and aggregation of recombinant
proteins under oxidative conditions. Indeed, Huleatt et al. (2008)
and Mozdzanowska et al. (2003) also used the same strategy
when they produced synthetic multiple antigenic peptides con-
taining four copies of M2e without affecting on its antigenecity.
The plasmid DNA, pGH-M2e, served as a template to generate the
4xM2e fusion gene according to the molecular strategy of our
previous study (Ebrahimi and Tebianian, 2010). The PCR product
was digested and then ligated to the 50 end of the C-terminal
domain of mycobacterium tuberculosis (H37Rv) HSP70 (mHSP70c)
in a prokaryotic expression vector containing a mHSP70c, pQE-
60/HSP70c, constructed from our previous study (Ebrahimi and
Tebianian, 2010). The schematic diagram of this fusion strategy is
demonstrated in Fig. 1.
The construct, pQE-60/4xM2e.HSP70c, was conﬁrmed by DNA
sequencing (MWG Biotech Co.,Germany).
The fusion protein was expressed in E. coli M15 cells, trans-
formed with the expression vectors pQE-60 (Qiagen, USA) bearing
4xM2e.HSP70c sequence exactly according to our previous study(33). Four hours after induction the bacteria was harvested and
the lysate was analyzed by SDS–PAGE.
Protein puriﬁcation and endotoxin measurement
Histidine (His)-tagged recombinant 4xM2e.HSP70c was pur-
iﬁed from an E. coli expression system as described previously
(Ebrahimi and Tebianian, 2010), using nickel afﬁnity chromato-
graphy (Ni-NTA agarose, Qiagen, USA) under denaturing condition
by following the manufacturer’s instructions.
To refold the puriﬁed denatured fusion protein, dialysis was
additionally performed by slowly diluting them in freshly made
50x Tris-HCl (pH 7.4) for 15 h at 4 1C, and Triton X-114 was then
used to remove its LPS, according to the method described in Aida
et al.(1990). Fusion protein was tested for the presence of
endotoxin by E-TOXATETM (limulus amebocyte lysate) test kit
(Sigma, USA). Endotoxin-levels were below 20 endotoxin units/
mg (o0.02 EU/mg).
After concentration through millipore ultraﬁltration-15 ml
(UF) system having a membrane with a molecular weight cut-
off of 10 kDa (Sartorius, Germany) and sterile ﬁltration through
0.22 mm, the puriﬁed fusion protein was stored in F105 buffer
which contains 10 mM Tris, 10 mM histidine, 5%(w/v) sucro-
se,75 mM NaCl, 0.1 mM EDTA, 0.5% (v/v) ethanol and 0.02%(w/v)
polysorbate-80 (pH 7.2) at 4 1C until use.
Puriﬁed fusion protein was characterized by Coomassie blue
staining and Western blotting analysis, and their concentrations
were determined using Micro BCA protein assay kit (Thermo
scientiﬁc, USA), according to the manufacturer’s instructions.
Experimental design
Three hundred and ninety 6-week-old female Balb/C mice
were purchased from the Animal Rearing Department of Pasteur
Institute, Iran. All of the mice at the age of 6-week-old were
randomly divided into thirteen 30-mouse groups (Table 1), and
kept two weeks for acclimatization before vaccination. They were
fed by standard grower diet throughout our experiment according
to the National Research Council Requirements (1995). Through-
out the study, challenged mice (Table 1; groups 2–13) were
housed in identical isolation rooms based on the same viral
isolate as the challenge virus and non-challenged mice (Table 1;
group 1) were housed in separate room.
Mice were reared, before and after vaccination, in four differ-
ent cages in each room with similar environmental conditions,
same availability of feeder and drinker conditions and offered
feed and drinking water ad libitum at the animal research unit of
Baqiyatallah University of Medical Sciences, Tehran, Iran. Before
the experiment, rooms and cages were vigorously washed and
fumigated using formaldehyde.
Virus preparation and titration
Iranian isolates of inﬂuenza viruses H3N2 and H1N1were
obtained as passaged in Mardin–Darby Canine Kidney (MDCK) cells
(a kindly gift from Dr. Mokhtari, Virus Research Dept., Tehran
University of Medical Science, Tehran, Iran), and avian inﬂuenza
virus, H9N2, was obtained as passaged in allantoic ﬂuid of 10-day-
old speciﬁc-pathogen-free (SPF) embryonated chicken eggs (a kindly
gift from Marand branch of Iran’s Razi Vaccine and Serum research
Institute). Viral lung-to-lung passages (10 serial passages) in Balb/C
mice and one passage in embryonated chicken eggs was also used to
obtain a mouse-adapted strains for inﬂuenza A/Tehran/631/2007
(H3N2), A/Tehran/5963/2010 (H1N1), and avian inﬂuenza A/chicken/
Iran/101/1998 (H9N2), according to previously described method
(Neirynck et al., 1999), and then stored in 80 1C. Infectious virus
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using MDCK cells and expressed as TCID50 units/ml.
Ninety percent mouse lethal doses (MLD90) of the inﬂuenza A
isolates H3N2, H1N1, or H9N2 were determined separately by
inoculating groups of 6- to 8-week-old female Balb/C mice (n¼
5/group) (Animal rearing Dept., Baqiyatallah University of Med-
ical Sciences, Tehran, Iran) by intranasal route during light
anesthesia with Ketamin/xylasine solution, with 30 ml of serial
10-fold dilutions of above mentioned isolates. The titer of the
propagated virus in cells and mice were then calculated by the
Reed and Muench (1938) method.
Mice immunization
Eight-week-old mice in the appropriate groups as shown
in Table 1 were each immunized twice (days 0 and 14) by the
intramuscular (IM) route with the puriﬁed 4xM2e.HSP70c fusion
protein administrated in F105 buffer (without conventional
adjuvants) at a dose of 0.1 ml containing 9 mg/mouse, with
injection of both quadriceps in 50 ml volume per site without
anesthesia. Conventional inactivated vaccines: egg-derived sub-
unit vaccine (inﬂuvacs, Solvay, Netherlands) and egg-derived
split vaccine (Split Virion, BP, Sanoﬁ Pasteur MSD,UK) of the
trivalent inﬂuenza vaccine formulations of vaccination season
2009/2010, consisting of inactivated virus strains A/Brisbane/59/
2007, A/Brisbane/10/2007 and B/Brisbane/60/2008 at a dose of
0.1 ml containing 9 mg/mouse were also administered to each
mice of the other groups twice (days 0 and 14) by IM injection of
both quadriceps in 50 ml volume per site without anesthesia,
separately, as shown in Table 1.
Mice of groups 1, 5, 9, and 13 (Table 1) were kept as
unimmunized controls and were injected intramuscularly with
equal volume of F105 buffer.
The mice were monitored for adverse reactions to vaccination
including redness, swelling, or the formation of granulomas at the
IM injection site. Mice were weighed daily for one week post
vaccination and weekly between the prime and the boost.
Serum samples analysis
Serum samples were obtained from each mouse by retro-
orbital bleeding in the time points of 1 day prior to the second
immunization (13 days after the ﬁrst immunization) and 2 days
prior to the viral challenges (13 days after the second immuniza-
tion) for the study of M2e- or HA-speciﬁc antibody responses.
Serum samples were also collected in the surviving mice on days
7 and 14 after viral challenges for detection of HA speciﬁc
antibody responses.
Serum samples from all groups and all time points were heat
inactivated at 56 1C for 30 min before being analyzed in ELISA or
hemagglutinin inhibition (HI) assays for analysis of anti-M2e or
HA-antibody responses, respectively.
The HI assay was carried out according to our previous study
(Ebrahimi et al., 2011) using b-propiolactone (BPL)-treated Iran/
H3N2, Iran/H1N1, or Iran/H9N2 antigens and 1% v/v suspension of
chicken red blood cells (RBCs). All samples were analyzed on the
same day, and HI titers were scored as the reciprocal of the highest
serum dilution producing 50% inhibition of hemagglutination.
The ELISA assay was performed as described previously (Zhao
et al., 2010) with some modiﬁcations. Brieﬂy, 96 well plates
(Maxisorb,Nunc, Denmark) were coated either with 1 mg/ml of
synthetic M2e-peptide (23 amino acids, 2 to 24, SLLTEVETPIR-
NEWGCRCNDSSD, synthesized by solid phase technology at the
GL Biochem, China), in 50 mM sodium bicarbonate buffer, pH 9.6,
and incubated overnight at 4 1C. After blocking, different serum
samples were loaded on peptide coated plates. The plates wereincubated with the different serum samples and then incubated
with 1:10000 goat anti-mouse IgG-HRP conjugates (Sigma-
Aldrich, USA), for 1 h at 37 1C. The color reaction was developed
with 3, 30, 5, 50-tetramethylbenzidine, TMB, (Pishtazteb, Tehran,
Iran), at OD 450 nm. For comparison between groups, the
averages of A450 values of different sera were analyzed. The
antibody titer is deﬁned as the reciprocal of the highest dilution
that yields an OD 450 nm value above 2 times the mean of
negative control wells.
Surface staining of virus-infected MDCK cells with anti-M2e
Sera were tested for reactivity with inﬂuenza A infected MDCK
cells as previously described (Ebrahimi and Tebianian, 2010).
Brieﬂy, Six-well plates were seeded with 107 Madin–Darby canine
kidney (MDCK) cells per well and until cells were near conﬂuence
they were infected (or left uninfected as a control) with 10
multiplicity of infection with H1N1, H3N2, or H9N2 inﬂuenza
isolates. Infected cells were incubated for 8 h at 37 1C. After
washing steps with PBS, the inﬂuenza A virus matrix protein
(M2) on the surface of infected MDCK cells were detected by sera
from mice immunized with 4xM2e.HSP70c (1:400 diluted in PBS).
The samples were stained with an FITC-labeled anti-mouse
IgG Ab (sigma, USA) and ﬂuorescence was visualized under an
inverted ﬂuorescence microscope (Olympus IX70). Here, the
uninfected cells were applied as negative control.
Viral challenge and follow-up
To assess efﬁcacy, mice immunized on days 0 and 14 as
described above were challenged in parallel on day 28 by
intranasal (i.n.) administration of an LD90 (dose lethal to 90% of
mice) of mouse adapted H3N2, H1N, or H9N2 inﬂuenza isolates
under light anesthesia with Ketamin/xylasine solution. Group 1 in
Table 1 containing non-vaccinated and non-challenged mice were
also kept as negative control, separately. Three mice in each group
were randomly selected as representatives for lung viral titration
on days 3, 6, and 9 post challenge and 21 mice in each challenged
group were observed by monitoring mortality on a daily basis
for 2 weeks. Morbidity was also followed at two-day intervals by
monitoring body weight and by measuring body weight and
observation of clinical symptoms. Mice that lost more than 25%
body weight were humanely euthanized.
Viral titration and histopathologic examination
To assess viral titer of infected mice with H3N2, H1N1, or
H9N2 inﬂuenza challenge isolates. Three mice from each infected
group were killed on days 3, 6, and 9 post challenge by cervical
dislocation under deep Ketamin/xylasine anesthesia, and their
lungs were harvested and then homogenized for evaluation of
viral load. Individual lungs were then titrated by inoculation of
decimal dilutions (102 to 108) of lung (lung homogenized
at 101 [wt./vol.] dilution) in Madin–Darby canine kidney
cells (MDCK) cell cultures as described previously (Rimmelzwaan
et al., 1998).
Viral titer in lung homogenate was expressed as log10 geo-
metric mean titer of TCID50/ml7SEM. The infectious titers were
calculated according to the method of Reed and Muench (1938)
using BPL-treated Iran/H3N2, Iran/H1N1, or Iran/H9N2 antigens.
All negative samples for the virus titration test were set at
0.9 log10 TCID50/ml.
Lungs from infected mice were also taken and ﬁxed in 10%
neutral formalin solution for histopathologic analysis on day
6 after challenge in order to be examined microscopically for
evidence of cellular inﬂammation and necrosis. The parafﬁn
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examination.
Statistical analysis
Data were analyzed using the SPSS 13.0 software (SPSS Inc.,
Chicago, USA).
Data were analyzed for signiﬁcance (Po0.05) by the one-way
analyses of variance when variance between groups was homo-
geneous and distribution of the data was normal or a nonpara-
metric test (Kruskal–Wallis) when normality test or homogeneity
of variance test failed.Acknowledgments
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